05/06/2025
cientists found that a new blood test analyzing cell-free DNA (cfDNA) in the bloodstream can detect many types of cancer early with impressive accuracy. This test used machine learning to study DNA fragments shed by tumors. In trials involving thousands of patients, the test showed an 87.4% sensitivity, meaning it correctly identified cancer cases, and a 97.8% specificity, meaning it rarely gave false positives. It could also predict the tissue where the cancer started about 83% of the time.
The test worked well even for early-stage cancers like liver, lung, ovarian, and pancreatic cancers, which are usually hard to detect early. In a study with asymptomatic people, the test identified over half of cancers within a year, many of which standard screenings missed.
These results suggest this cfDNA-based test could be a powerful new tool to catch cancer earlier and guide treatment decisions, potentially saving more lives by spotting cancers sooner than current methods allow.
